-+ 0.00%
-+ 0.00%
-+ 0.00%

Shield Therapeutics to Take Over US Commercialization of ACCRUFeR

MT Newswires·08/28/2026 00:45:26
Listen to the news
12:45 AM EDT, 08/28/2026 (MT Newswires) -- Shield Therapeutics (STX.L) said Thursday it agreed to assume full commercial responsibility for ACCRUFeR in the US under a deal with healthcare company Viatris (VTRS.VI, VIA.F). As agreed, the London-listed pharmaceutical company will oversee all commercial activities for the drug in the US, including pricing and marketing. Shield Therapeutics anticipates immediate value gain from the transaction, which is expected to close by Sept. 30. ACCRUFeR is a non-salt-based oral therapy for patients suffering from iron deficiency, with or without anemia.